论文部分内容阅读
目的:探讨利妥昔单抗(rituximab)联合CHOP化疗治疗B细胞非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)的临床疗效及其对钙网蛋白(calreticulin,CRT)表达的影响。方法:选取南通大学附属医院2008年7月至2011年2月期间48例初治B细胞NHL,分为利妥昔单抗联合CHOP化疗组(R-CHOP组,25例)和CHOP组(23例)两组,6个疗程后比较两组患者的临床疗效、不良反应,以及外周血中CD20+B细胞表面CRT的表达。结果:R-CHOP组B细胞NHL患者完全缓解率为80.0%,总有效率为92.0%;CHOP组完全缓解率为56.5%,总有效率为69.6%;R-CHOP组患者完全缓解率以及总有效率高于CHOP组(P<0.05)。两组间不良反应相似,R-CHOP联合治疗没有增加NHL患者治疗后的不良反应。R-CHOP组患者治疗后外周血中CD20+B细胞表面CRT的表达明显高于CHOP组[(255.00±5.57)vs(216.00±3.61),P<0.05]。结论:利妥昔单抗联合CHOP化疗治疗B细胞NHL较常规CHOP化疗效果好,可能与联合治疗上调CRT表达有关。
Objective: To investigate the clinical efficacy of rituximab in combination with CHOP chemotherapy in the treatment of non-Hodgkin’s lymphoma (NHL) and its effect on the expression of calreticulin (CRT). Methods: Forty-eight patients with untreated B lymphocytes from July 2008 to February 2011 were randomly divided into rituximab combined with CHOP chemotherapy group (R-CHOP group, 25 cases) and CHOP group (23 cases) Cases) were divided into two groups. After six courses of treatment, the clinical efficacy, adverse reactions, and the expression of CRT on the surface of CD20 + B cells in peripheral blood were compared. Results: The complete remission rate was 80.0% and the total effective rate was 92.0% in B-cell NHL patients in R-CHOP group. The complete remission rate was 56.5% in CHOP group and the total effective rate was 69.6%. The complete remission rate, Efficacy than the CHOP group (P <0.05). Adverse reactions were similar between the two groups, R-CHOP did not increase the combination therapy NHL patients after treatment of adverse reactions. The expression of CRT on the surface of CD20 + B cells in peripheral blood of R-CHOP group was significantly higher than that of CHOP group [(255.00 ± 5.57) vs (216.00 ± 3.61), P <0.05]. Conclusion: Rituximab combined with CHOP chemotherapy for B cell NHL is more effective than conventional CHOP chemotherapy, which may be related to the increase of CRT expression by combination therapy.